Combination immunotherapy and parp inhibitor for triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This study tests a combination of two drugs — an immunotherapy (QL1706) and a PARP inhibitor (olaparib) — to see if it can help people with triple-negative breast cancer that has come back or spread, especially when their tumors have a specific DNA repair problem (HRD). It is for people who have already tried at least one prior treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old and are female.
- Your breast cancer is triple-negative and has either come back or spread to other parts of the body.
- You have a BRCA1/2 mutation or another sign of homologous recombination deficiency (HRD) — a specific repair issue in your cancer cells.
- You have already had at least one, but not more than two, prior treatments for your cancer.
- You are generally active and able to take care of yourself (ECOG score of 0 or 1).
- You have not previously been treated with an immunotherapy drug or a PARP inhibitor.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with a PARP inhibitor (olaparib) and a chemotherapy drug (paclitaxel) before surgery for early high-risk triple negative breast cancer that is HRD positive. It aims to shrink or eliminate the tumor to improve long-term outcomes.
This Phase 2 trial studies a treatment given around the time of breast surgery to help shrink or control residual (remaining) triple-negative breast cancer. It also checks biomarkers (lab signals) to understand who benefits, with some people receiving anti–PD-L1 immunotherapy and some not.
This trial tests an experimental drug called QLC5513, either by itself or combined with another drug (QL1706), for people with triple-negative breast cancer that has continued to grow despite prior treatment. The goal is to see if this new approach can shrink tumors or slow the cancer's progression, and it might be an option if standard treatments have stopped working.
This trial tests a combination of an immunotherapy drug (QL1706) plus standard chemotherapy given before surgery to shrink triple-negative breast cancer. The goal is to see if this approach helps remove the tumor more completely.
This study tests a new combination of two immunotherapy drugs (iparomlimab and tuvonralimab) given with standard chemotherapy, compared to chemotherapy alone, for people with triple-negative breast cancer that has spread and hasn't been helped by earlier treatments. The goal is to see if adding this immunotherapy can shrink tumors or slow the cancer's growth better than chemotherapy alone.
This study tests a new drug combination (QL1706 plus olaparib) for people with HER2-negative breast cancer that has progressed after earlier treatments. It aims to see if this combo can help shrink tumors or slow the cancer when the tumor has a specific DNA repair deficiency.
Hear when a new Triple-Negative Breast Cancer (TNBC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.